Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print March 4, 2008
DOI: 10.2337/db07-0739

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0739v1
57/6/1629    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belmadani, S.
Right arrow Articles by Matrougui, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belmadani, S.
Right arrow Articles by Matrougui, K.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Elevated Epidermal Growth Factor Receptor Phosphorylation Induces Resistance Artery Dysfunction in Diabetic db/db mice

Souad Belmadani, Ph.D1, Desiree I Palen, MS2, Romer A Gonzalez-Villalobos3, Hamid A Boulares, Ph.D2, and Khalid Matrougui, Ph.D2

1Department of Physiology, LSU Health Sciences Center, 1901 Perdido Street, New Orleans LA 70112
2Department of Pharmacology, LSU Health Sciences Center, 1901 Perdido Street, New Orleans LA 70112
3Department of Physiology, Tulane University, 1430 Tulane Ave, New Orleans LA 70112, and Hypertension and Renal Biology Center of Excellence

Objective: We previously showed epidermal growth factor receptor (EGFR) transactivation as key mechanism in the regulation of resistance artery myogenic tone. Type 2 diabetes is associated with microvascular complications. We hypothesized that elevated EGFR phosphorylation contributes to resistance artery dysfunction in type 2 diabetes.

Methods-Results: Diabetic db/db (diabetic) and non-diabetic (control) mice were treated with EGFR inhibitor (AG1478, 10 mg/kg/day) for 2 weeks. Isolated coronary artery (CA) and mesenteric resistance artery (MRA) were mounted in an arteriograph. Pressure-induced myogenic tone (MT) was increased in MRA and CA from diabetic mice and normalized by AG1478. Phenylephrine-induced contraction and nitric oxide donor-induced relaxation were similar in all groups. Relaxation endothelium-dependent in response to shear-stress and acetylcholine of MRA and CA from diabetic mice were altered and associated with reduced eNOS expression and phosphorylation. Treated diabetic mice with AG1478 improved CA and MRA endothelial function and restored eNOS expression. Immunostaining and western blot analysis showed increased endothelial and SMC EGFR phosphorylation of MRA and coronary from diabetic mouse, which was reduced by AG1478.

Primary cultured endothelial cells (EC), from resistance arteries, treated with high glucose for 48hrs showed an increase of EGFR phosphorylation associated with eNOS expression and phosphorylation decrease in response to calcium ionophore. Pretreatment of endothelial cells with AG1478 prevented the effect of high glucose.

Conclusion: This study provides evidence of the role of elevated EGFR phosphorylation in CA and MRA dysfunction in diabetic db/db mice. Therefore, EGFR should be a potential target for overcoming diabetic small arteries complications.


Correspondence: kmatroug{at}tulane.edu

Key Words: resistance artery • myogenic tone • flow-induced dilation • eNOS • EGF receptor • Type 2 diabetes, and • diabetic db/db mice


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.